Key result
LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, has proven effective in hypertension and is being tested in large outcomes trials for heart failure.
LCZ696 is a novel angiotensin receptor neprilysin inhibitor being evaluated for the treatment of heart failure.
LCZ696 merits outcomes evaluation in heart failure; leaves open whether hypertension efficacy will improve survival.
Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide. LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction. A preserved ejection fraction outcomes trial is beginning. Clinical Pharmacology & Therapeutics (2013); 94 4, 445–448. doi:10.1038/clpt.2013.146
No takes yet. Share an insight, caveat, or question.
Vardeny et al. (2013) conducted a review in Heart failure. LCZ696 was evaluated. LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, has proven effective in hypertension and is being tested in large outcomes trials for heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: